Teva faces EU antitrust probe over MS drug CopaxoneThe European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company Share XTeva faces EU antitrust probe over MS drug Copaxonehttps://pharmaphorum.com/news/teva-faces-eu-antitrust-probe-over-ms-drug-copaxone/
COVID-19 increased demands on carers’ wellbeing, study findsCOVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, Share XCOVID-19 increased demands on carers’ wellbeing, study findshttps://pharmaphorum.com/news/covid-19-increased-demands-on-informal-carers-wellbeing-study-finds/
BMS’ MS pill gets funding in Scotland after rejection in England by NICEScotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide Share XBMS’ MS pill gets funding in Scotland after rejection in England by NICEhttps://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/
CHMP clears way for EU approval of Novartis’ MS drugNovartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, Share XCHMP clears way for EU approval of Novartis’ MS drughttps://pharmaphorum.com/news/chmp-clears-way-for-eu-approval-for-novartis-ms-drug/
NICE rejects BMS’ Zeposia MS pill in provisional guidanceNICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing Share XNICE rejects BMS’ Zeposia MS pill in provisional guidancehttps://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/
Clene goes public with gold-based neurology nanotechnologyBiotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat Share XClene goes public with gold-based neurology nanotechnologyhttps://pharmaphorum.com/news/clene-goes-public-with-gold-based-neurology-nanotechnology/
Bridging the gap between pharma and the NHS in MSJanette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis Share XBridging the gap between pharma and the NHS in MShttps://pharmaphorum.com/views-analysis-patients/bridging-gap-between-pharma-nhs-in-ms/
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bnEli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of Share XLilly to buy private biotech Disarm Therapeutics for up to $1.36bnhttps://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/
NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
